BACKGROUND: Schistosomiasis-associated pulmonary arterial hypertension (Sch-PAH) may be one of the most prevalent forms of pulmonary arterial hypertension (PAH) worldwide. However, the clinical and hemodynamical response to specific PAH therapy in Sch-PAH is not known. METHODS: We retrospectively analyzed the charts of all patients with Sch-PAH who initiated specific PAH treatment between June 2003 and June 2010 in a single PAH reference center in São Paulo, Brazil. Clinical and hemodynamical data were retrospectively collected and evaluated in two periods: baseline and posttreatment. RESULTS: The study population consisted of 12 patients with Sch-PAH. They were treated with phosphodiseterase-5 inhibitors (seven patients), endothelin receptor antagonists (four patients), or combination therapy (one patient). Mean treatment period was 34.9 ± 15.5 months. Patients with Sch-PAH presented significant improvements in terms of functional class, 6-min walk test distance (439 ± 85 to 492 ± 79 m, P = .032), cardiac index (2.66 ± 0.59 to 3.08 ± 0.68 L/min/m(2), P = .028), and indexed pulmonary vascular resistance (20.7 ± 11.6 to 15.9 ± 9 W/m(2), P = .038) with the introduction of specific PAH treatment. CONCLUSIONS: We conclude that specific PAH therapy may be of benefit to patients with Sch-PAH, considering clinical, functional, and hemodynamic parameters.
BACKGROUND:Schistosomiasis-associated pulmonary arterial hypertension (Sch-PAH) may be one of the most prevalent forms of pulmonary arterial hypertension (PAH) worldwide. However, the clinical and hemodynamical response to specific PAH therapy in Sch-PAH is not known. METHODS: We retrospectively analyzed the charts of all patients with Sch-PAH who initiated specific PAH treatment between June 2003 and June 2010 in a single PAH reference center in São Paulo, Brazil. Clinical and hemodynamical data were retrospectively collected and evaluated in two periods: baseline and posttreatment. RESULTS: The study population consisted of 12 patients with Sch-PAH. They were treated with phosphodiseterase-5 inhibitors (seven patients), endothelin receptor antagonists (four patients), or combination therapy (one patient). Mean treatment period was 34.9 ± 15.5 months. Patients with Sch-PAH presented significant improvements in terms of functional class, 6-min walk test distance (439 ± 85 to 492 ± 79 m, P = .032), cardiac index (2.66 ± 0.59 to 3.08 ± 0.68 L/min/m(2), P = .028), and indexed pulmonary vascular resistance (20.7 ± 11.6 to 15.9 ± 9 W/m(2), P = .038) with the introduction of specific PAH treatment. CONCLUSIONS: We conclude that specific PAH therapy may be of benefit to patients with Sch-PAH, considering clinical, functional, and hemodynamic parameters.
Authors: Rahul Kumar; Claudia Mickael; Jacob Chabon; Liya Gebreab; Alleluiah Rutebemberwa; Alexandra Rodriguez Garcia; Daniel E Koyanagi; Linda Sanders; Aneta Gandjeva; Mark T Kearns; Lea Barthel; William J Janssen; Thais Mauad; Angela Bandeira; Eric Schmidt; Rubin M Tuder; Brian B Graham Journal: Am J Respir Crit Care Med Date: 2015-10-15 Impact factor: 21.405
Authors: Rahul Kumar; Claudia Mickael; Biruk Kassa; Liya Gebreab; Jeffrey C Robinson; Daniel E Koyanagi; Linda Sanders; Lea Barthel; Christina Meadows; Daniel Fox; David Irwin; Min Li; B Alexandre McKeon; Suzette Riddle; R Dale Brown; Leslie E Morgan; Christopher M Evans; Daniel Hernandez-Saavedra; Angela Bandeira; James P Maloney; Todd M Bull; William J Janssen; Kurt R Stenmark; Rubin M Tuder; Brian B Graham Journal: Nat Commun Date: 2017-05-30 Impact factor: 14.919
Authors: Fernando Antônio Botoni; Carolina Coimbra Marinho; Vinicius Tostes Carvalho; Claudia S Mickael; Brian B Graham Journal: Int J Cardiol Heart Vasc Date: 2019-07-05
Authors: Carlos G Piscoya Roncal; Adriano A Mendes; Maria T C Muniz; Sheilla A de Oliveira; Leonidas M do Valle Neto; Nathália A de Vasconcellos Piscoya; Gustavo H B Góes; Dario C Sobral Filho; Mardi Gomberg-Maitland Journal: Int J Cardiol Heart Vasc Date: 2019-10-31
Authors: Susana Hoette; Claudia Figueiredo; Bruno Dias; Jose Leonidas Alves; Francisca Gavilanes; Luis Felipe Prada; Dany Jasinowodolinski; Luciana Tamie Kato Morinaga; Carlos Jardim; Caio Julio Cesar Fernandes; Rogério Souza Journal: BMC Pulm Med Date: 2015-10-12 Impact factor: 3.317
Authors: Caio J C S Fernandes; Barbara C S Martins; Carlos V P Jardim; Rozana M Ciconelli; Luciana K Morinaga; Ana Paula Breda; Susana Hoette; Rogério Souza Journal: Health Qual Life Outcomes Date: 2014-08-30 Impact factor: 3.186